Radiotherapy Utilization in Traditional Medicare and Medicare Advantage DOI Creative Commons
Jacob Hogan,

E. John Orav,

Tianfeng Zhang

и другие.

JAMA Network Open, Год журнала: 2025, Номер 8(4), С. e253018 - e253018

Опубликована: Апрель 2, 2025

As more than 50% of Medicare beneficiaries are enrolled in Advantage (MA), understanding whether the treatment covered by MA vs traditional (TM) is comparable can aid providing high-value care. majority patients with cancer undergo radiotherapy, it important to quantify TM and utilization oncology. To analyze primary type radiotherapy technology used, length, estimated spending for undergoing compared cancer. This retrospective cross-sectional study used 2018 claims data aged 65 years or older who received 1 15 types. Analyses were performed between May December 28, 2024. Insurance (MA TM), type, age, dual-eligibility status, medical comorbidities, county, center type. Primary 90-day episodes. Adjusted rates odds ratios (ORs) calculated compare types rate (RRs) length Of 31 563 episodes among 30 941 patients, 22 594 (71.58%) (mean [SD] 74.76 [6.57] years; 50.76% males) 8969 (28.42%) 74.51 [6.24] 51.78% males). For MA, adjusted analyses revealed lower proton therapy use (52 [0.58% (95% CI, 0.34%-0.82%)] 373 [1.65% 1.50%-1.80%)]; OR, 0.36 [95% 0.27-0.48]) stereotactic (1235 [13.77% 13.13%-14.41%)] 3391 [15.01% 14.61%-15.41%)]; 0.87 0.81-0.95]), higher 2- 3-dimensional (3962 [44.17% 43.39%-44.96%)] 9584 [42.43% 41.93%-42.92%)]; 1.13 1.06-1.21]), greater mean (21.38 21.14-21.61] 19.48 19.33-19.62] treatments; RR, 1.10 1.08-1.11]), ($8677.56 $8566.58-$8788.54] $8393.20 $8323.34-$8463.05]; 1.04 1.02-1.06]) TM. In this study, had those Despite expensive advanced modalities, was not associated cost savings. Whether meets value proposition radiation oncology requires further investigation.

Язык: Английский

Precision Treatment of Pulmonary Sarcoma Metastasis Using Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy: A Case Report DOI Open Access
Anastasia Stergioula,

Theodoros Kormas,

Stefania Kokkali

и другие.

Cureus, Год журнала: 2025, Номер unknown

Опубликована: Апрель 11, 2025

Язык: Английский

Процитировано

0
Radiotherapy Utilization in Traditional Medicare and Medicare Advantage DOI Creative Commons
Jacob Hogan,

E. John Orav,

Tianfeng Zhang

и другие.

JAMA Network Open, Год журнала: 2025, Номер 8(4), С. e253018 - e253018

Опубликована: Апрель 2, 2025

As more than 50% of Medicare beneficiaries are enrolled in Advantage (MA), understanding whether the treatment covered by MA vs traditional (TM) is comparable can aid providing high-value care. majority patients with cancer undergo radiotherapy, it important to quantify TM and utilization oncology. To analyze primary type radiotherapy technology used, length, estimated spending for undergoing compared cancer. This retrospective cross-sectional study used 2018 claims data aged 65 years or older who received 1 15 types. Analyses were performed between May December 28, 2024. Insurance (MA TM), type, age, dual-eligibility status, medical comorbidities, county, center type. Primary 90-day episodes. Adjusted rates odds ratios (ORs) calculated compare types rate (RRs) length Of 31 563 episodes among 30 941 patients, 22 594 (71.58%) (mean [SD] 74.76 [6.57] years; 50.76% males) 8969 (28.42%) 74.51 [6.24] 51.78% males). For MA, adjusted analyses revealed lower proton therapy use (52 [0.58% (95% CI, 0.34%-0.82%)] 373 [1.65% 1.50%-1.80%)]; OR, 0.36 [95% 0.27-0.48]) stereotactic (1235 [13.77% 13.13%-14.41%)] 3391 [15.01% 14.61%-15.41%)]; 0.87 0.81-0.95]), higher 2- 3-dimensional (3962 [44.17% 43.39%-44.96%)] 9584 [42.43% 41.93%-42.92%)]; 1.13 1.06-1.21]), greater mean (21.38 21.14-21.61] 19.48 19.33-19.62] treatments; RR, 1.10 1.08-1.11]), ($8677.56 $8566.58-$8788.54] $8393.20 $8323.34-$8463.05]; 1.04 1.02-1.06]) TM. In this study, had those Despite expensive advanced modalities, was not associated cost savings. Whether meets value proposition radiation oncology requires further investigation.

Язык: Английский

Процитировано

0